---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-006915"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:48:38.172738+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tonix doses first participant in Phase 1 study of TNX-1900 for migraine and craniofacial pain

## Summary
- First participant dosed in Phase 1 investigator-initiated study of TNX-1900 (intranasal potentiated oxytocin).
- Study evaluates effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation in healthy female volunteers.
- Principal investigator Dr. Antoinette Maassen van den Brink, Erasmus University Medical Center.
- TNX-1900 targets a distinct pathway from CGRP inhibitors and triptans, blocking CGRP release in animal models.
- Use of Laser Speckle Contrast Imaging (LSCI) for real-time dermal blood flow measurements.

## SEC filing metadata
- accession: 0001999371-26-006915
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126006915/0001999371-26-006915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126006915/tnxp-8k_032526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-006915
- JSON: https://secwatch.observer/filing/0001999371-26-006915.json
- Plain text: https://secwatch.observer/filing/0001999371-26-006915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.